Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Cytox Appoints New Chairman
February 1, 2015
Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, today announced the appointment of new Chairman, Dr Andrew Carr.
Dr Carr has been working closely with Cytox in an advisory capacity and replaces entrepreneurial investor, David Evans, who steps down after 4 years as Chairman.
Dr Richard Pither, CEO of Cytox, commented, We would like to acknowledge the excellent leadership David Evans has brought to Cytox during his tenure as Chairman. David has worked closely with the Board to identify his replacement and we are pleased to welcome Dr Andrew Carr, who brings a wealth of experience to see us through the next exciting phase of our genetic-based blood test.
Dr Carr has experience in both large international companies, such as Amersham Biosciences, GE Healthcare and Thermo Fisher Scientific, as well as smaller biotechs Teraview, deltaDOT and BAC B.V.